FLT3 and cancer: Considering studies conducted by our research group in the search for new promising inhibitors of Aurora B kinase [10] and the current results, the IAF79 compound (Table 5) can be considered to be a promising dual Aurora B/FLT3 inhibitor aimed at the treatment of different cancer types, including myeloid leukemia, as it presents considerable predicted activity and energy values for both targets studied.